Advanced MedTech Holdings (AMTH), a global medical leader headquartered in Singapore and a wholly-owned subsidiary of Temasek, announced that the RESOLUTE 2.0 direct RT-PCR test kit has received approval from Australia’s Therapeutic Goods Administration (TGA) for use by laboratories and medical institutions across Australia.

An industry-first direct RT-PCR COVID-19 test kit that eliminates the need for viral RNA extraction from patient test samples, RESOLUTE 2.0 is only among a handful of such RT-PCR tests approved by TGA and stands out with its high sensitivity and specificity to SARS-CoV-2 despite a shortened laboratory processing time. This minimises potential human errors while reducing the exposure of lab technicians to the virus, and delivers test results in half the time compared to other ‘gold standard’ conventional RT-PCR test kits. Given that high-volume processing of fast and accurate COVID-19 tests is critical to reopen economies and trade safely, the RESOLUTE 2.0 can be paired with the complementary RAVE automated robotics lab system to process an industry-topping four times more throughput than the usual RT-PCR test volume in a day.

As a key weapon in the testing arsenal of medical facilities and laboratories globally, the RESOLUTE 2.0 will be used at a new COVID-19 testing lab that will open in Changi Airport in 2021.

Besides nasopharyngeal (NP) COVID-19 testing, the versatile RESOLUTE 2.0 test kit has recently received approvals for deep-throat saliva (DTS) and oropharyngeal/middle turbinate (OPMT) testing from Singapore’s Health Sciences Authority.

The RESOLUTE 2.0 kit was jointly developed by Singapore’s Agency for Science, Technology and Research (A*STAR) and DSO National Laboratories while the RAVE was developed by A*STAR. The integrated RESOLUTE 2.0 and RAVE system is distributed by AMTH globally.